Combined oral contraceptive (COC) use is an established factor that consistently reduces the risk for epithelial ovarian cancer (EOC; [@bib1]). Less is known about the association between EOC risk and COC use with respect to the timing of full-term births. Increasing parity reduces EOC risk ([@bib8]), but it is difficult to tease apart the independent effects of COC use and parity. The total number of ovulatory years between menarche and menopause has been used, but this does not address the timing of COC use with respect to full-term births. Studies of breast cancer ([@bib18]; [@bib17]; [@bib9]) and endometrial cancer ([@bib4]) have reported a long-term effect with the use of COCs before the first full-term pregnancy (FFTP) among parous women. We therefore investigated the EOC risk associated with COC use, focusing on COC use before the FFTP.

Materials and methods
=====================

This Canadian population-based case--control study has been previously described ([@bib5]) including ethics approvals (Conjoint Health Research Ethics Board, Calgary, Alberta (AB) and Research Ethics Board, British Columbia (BC) Cancer Agency, Vancouver, BC) and written informed consent. Briefly, cases were identified from the population-based BC and AB cancer registries who were: age 20--79 years (40--79 in AB); diagnosed with first primary, incident, histologically confirmed EOC (invasive EOC in AB); and able to complete study in English. A total of 1505 cases (60% of 2522 eligible) completed the study. Eligible controls identified from provincial health rosters and a mammography screening program ([@bib6]) were: aged 20--79 years (40--79 in AB); able to complete study in English; and, had at least one ovary. A total of 2564 (53% of 4838 eligible) completed the study.

Risk factor information was ascertained through the diagnosis date (month/year) for cases and an assigned reference date (month/year) for controls based on an age-frequency match with cases. Respondents completed a self-administered questionnaire (BC before 2005) or a telephone interview (AB and BC after 2005). In additional to demographic, lifestyle, and medical/reproductive factors, women provided information on COC use, including dates or ages of use. Specific COC names were not ascertained. Histotypes were determined by re-review of haematoxylin and eosin slides according to contemporary criteria ([@bib10]) for 979 women (85.6%).

The analysis was restricted to those ⩾40 years of age at diagnosis/reference date (1144 invasive cases and 2513 controls). Combined oral contraceptive use was evaluated as: non-use (never or \<0.5 years) *vs* ever use (⩾0.5 years); continuous duration (years, ever users only) and, as categorical duration (non-use, \<5 years, 5--10, ⩾10 years, and unknown). We used logistic regression to estimate adjusted odds ratios (aORs) and 95% confidence intervals (CIs) in R software ([@bib16]). All variables in [Table 1](#tbl1){ref-type="table"} were evaluated as potential confounders. Final aORs included matching variables (Alberta, BC before 2005, BC after 2005, and 40--49, 50--59, 60--69, ⩾70 years of age), parity (0, 1, 2, ⩾3 or 1, 2, ⩾3 when restricted to parous women), age at FTTP (⩽24, 25--29, ⩾30 years), breastfeeding (never, ever), first degree family female breast or ovarian cancer (no, yes), tubal ligation (no, yes), and BMI (\<25, 25--29.9, 30--34.9, ⩾35 kg m^−2^). Other variables did not alter the estimated ORs by more than 10%. Histotype-specific analyses were restricted to high-grade serous and combined endometrioid/clear cell, due to few cases of other histotypes. Because COC use exclusively before and exclusively after the FFTP were mutually exlcusive, they were modelled simultaneously, allowing direct comparisons of the two risk estimates using contrasts ([@bib13]).

Results
=======

Characteristics of parous cases and controls are described in [Table 1](#tbl1){ref-type="table"}. Combined oral contraceptive use was common among parous women, reported by 61% of cases and 80% of controls. With respect to the timing of COC use ([Table 2](#tbl2){ref-type="table"}), use of COCs before and after the FFTP (aOR=0.45, 95% CI=0.34--0.59; per year of use: aOR=0.94, 95% CI=0.91--0.98) as well as exclusive use before the FFTP (aOR=0.56, 95% CI=0.42--0.75; per year of use: aOR=0.91, 95% CI=0.86--0.96) was associated with a reduced risk for EOC. Similarly, both before and after the FFTP as well as use exclusively before the FFTP was associated with a reduced risk for both high-grade serous (aOR=0.50, 95% CI=0.35--0.72 and aOR=0.49, 95% CI=0.35--0.70, respectively) and endometrioid/clear cell (aOR=0.52, 95% CI=0.29--0.92 and aOR=0.47, 95% CI=0.27--0.83, respectively) EOC. In contrast, COC use exclusively after the first birth was associated with a smaller reduction in EOC risk (aOR=0.78, 95% CI=0.61--1.01) that was suggestive but there was no association with increasing duration (per year of use aOR=0.98, 95% CI=0.95--1.02). When the risk estimate for exclusive use before the FFTP was compared (via contrasts) with the risk estimate for exclusive use after, the aORs were found to be significantly different (*P*-value, \<0.01) ([Table 2](#tbl2){ref-type="table"}).

When we stratified by age at FFTP, COC use before and after as well as exclusively before the FFTP was consistently associated with a reduction in EOC risk regardless of age at first birth, a consistency that was not seen with COC use exclusively after the FFTP ([Figure 1](#fig1){ref-type="fig"}), although some results were unstable. Similar results were noted when stratified by parity, although risk estimates were more similar for parity ⩾3 ([Figure 1](#fig1){ref-type="fig"}).

The association of COC use and EOC risk for our entire study population (both parous and non-parous women combined) was consistent with the reported literature ([Supplementary Tables 1--4](#sup1){ref-type="supplementary-material"}). Any COC use was associated with a reduction in risk (aOR=0.58, 95% CI=0.49, 0.69). Among COC users, risk was most strongly reduced with longer durations of use overall, within more recent time since last use, and for younger ages at first use.

Conclusion
==========

When we assessed the timing of COC use exclusively before the FFTP among parous women, we found a strong reduction in risk (∼40%), which was almost as strong as the ∼50% risk reduction seen with COC before and after the FFTP. Even for fairly short-term COC use (\<5 years) before the FFTP there was a significant and substantial reduction in risk years later in parous women. This result is surprising, given that these women all experienced the reduction in risk associated with being parous, and given that the literature ([@bib1]) and our own results for parous and non-parous women indicating that last use of COCs in the more distant past is associated with weaker reductions in risk. In contrast, the effect of such use after the FTTP was of lesser magnitude, despite the assumption that the cessation of ovulation in these women should have equivalent effects regardless of the timing of COCs.

Consistent with our findings, other studies have reported that any use of COCs before age 20 years ([@bib14]; [@bib11]; [@bib1]; [@bib12]) or 25 years ([@bib2]) is associated with a reduced EOC risk of 29--50% many years later. Ours is the first study to assess COC use exclusively before and after the FFTP to evaluate the timing of COC use with pregnancy.

Although the more immediate effects of COC use on biological end points such as hormone levels, gene expression, and ovulation are well documented, the long-term effects on EOC risk are largely attributed to fewer ovulations during reproductive life ([@bib7]), with the assumption that the timing of ovulation reduction does not matter. Our results could be due, in part, to fewer ovulations because of COC use, but it is not clear why use before the FFTP would have such a strong, lasting impact on EOC risk. In breast cancer, the elevated risk noted with COC use before the FFTP has been hypothesised to be related to the carcinogenic susceptibility of undifferentiated breast tissue at this time ([@bib17]), and in endometrial cancer the reduction in risk with early COC use is unknown but may be related to a lasting effect on hormone levels that reduce cellular proliferation ([@bib3]). Whether such mechanisms are also applicable to a long-lasting reduction in EOC risk is not clear. Regardless of the tissue of origin for EOC (fallopian tube, endometrium, ovary, etc.), our results suggest that the timing of ovulation reduction is important, and that there may be other long-term mechanisms for an EOC risk reduction beyond ovulation that manifest before the FFTP.

Study strengths include the population-based design; large sample size; restriction to first primary, histologically confirmed invasive EOC; detailed information on parity; assessment of contemporary histotypes ([@bib10]); high prevalence of COC use; and, restriction to parous women with adjustment for parity, thus minimising confounding by parity. Limitations include: no COC name/dosage information; cases recalling past COC use more fully than controls (but that would bias risk estimates to the null value); relatively low response percentage among the control women; and, possible residual confounding. In addition, COC use in this study represents formulations of COC available in the past, and current formulations may not have the same long-term effects.

In summary, the significant reduction in EOC risk observed with COC use before the FFTP among parous women is a novel and requires replication. Despite the consistently reported risk reduction in EOC with COCs, questions remain about the timing of use and the underlying biological mechanisms of long-term effects to guide future EOC risk prediction ([@bib15]) and directed chemoprevention strategies for high-risk women ([@bib19]).
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![**Combined oral contraceptive use with respect to the FFTP by age at first birth (**A**) and by number of births (parity) (**B**) among parous women.** The aORs are adjusted for the following: study site (Alberta, BC before 2005, BC after 2005); age (40--49, 50--59, 60--69, ⩾70 years); parity in Panel **A** only (1, 2, ⩾3); age at FFTP in Panel **B** only (⩽24, 25--29.9, 30--34.9, ⩾35 years); breastfeeding (never, ever); first degree female family history of breast or ovarian cancer (no, yes); tubal ligation (no, yes); BMI (\<25, 25--29.9, 30--34.9, ⩾35 kg m^−2^).](bjc2016400f1){#fig1}

###### Characteristics of invasive, epithelial ovarian cancer cases and controls, parous women only, OVAL-BC, 2002--2012

                                                    **Cases,** ***N*****=854**   **Controls,** ***N*****=2139**          
  ------------------------------------------------- ---------------------------- -------------------------------- ------ -----
  **Age (years)**                                                                                                        
  40--49                                            113                          13                               423    20
  50--59                                            272                          32                               773    36
  60--69                                            278                          33                               670    31
  ⩾70                                               191                          22                               273    13
  **Race**                                                                                                               
  White                                             711                          83                               1877   88
  Chinese/Japanese                                  35                           4                                57     3
  Other Asian                                       24                           3                                44     2
  Others                                            54                           6                                96     4
  Unknown                                           30                           4                                64     3
  **Education**                                                                                                          
  High school or less                               357                          42                               755    35
  Vocational school                                 216                          25                               573    27
  University                                        280                          33                               809    38
  Unknown                                           1                            \<1                              2      \<1
  **BMI (kg** **m**^**−2**^)                                                                                             
  \<25                                              406                          48                               1015   47
  25--29.9                                          274                          32                               682    32
  30--34.9                                          101                          12                               278    13
  ⩾35                                               73                           9                                161    8
  Unknown                                           0                            0                                3      \<1
  **Smoking**                                                                                                            
  Never                                             409                          48                               1046   49
  Current                                           95                           11                               156    7
  Former                                            350                          41                               937    44
  **Family history breast and/or ovarian cancer**                                                                        
  No                                                673                          79                               1767   83
  Yes                                               163                          19                               328    15
  Unknown                                           18                           2                                44     2
  **Menopausal status and HT**                                                                                           
  Pre-menopausal                                    170                          20                               584    27
  Peri, post-menopausal                                                                                                   
   No HT                                            399                          47                               933    44
   Oestrogen only                                   131                          15                               252    12
   Oestrogen plus progesterone only                 101                          12                               252    12
   Other HT                                         53                           6                                114    5
  Unknown                                           0                            0                                4      \<1
  **COC**                                                                                                                
  No (never or \<6 months)                          452                          39                               506    20
  Yes                                               692                          61                               2007   80
  Yes, duration (years)                                                                                                   
   \<5                                              367                          32                               918    37
   5--10                                            185                          16                               564    22
   ⩾10                                              128                          11                               504    20
  Unknown                                           12                           1                                21     1
  **Parity**                                                                                                             
  1                                                 389                          46                               1080   50
  2                                                 288                          34                               736    34
  ⩾3                                                177                          21                               323    15
  **Age at FFTP (years)**                                                                                                
  ⩽24                                               561                          65                               1417   66
  25--29                                            91                           11                               299    14
  ⩾30                                               196                          23                               402    19
  Unknown                                           6                            1                                21     1
  **Ever breastfed**                                                                                                     
  No                                                229                          27                               424    20
  Yes                                               625                          73                               1714   80
  Unknown                                           0                            0                                1      \<1
  **Duration breastfeeding (months)**                                                                                    
  Never                                             229                          27                               424    20
  \<10                                              386                          45                               872    41
  ⩾10                                               237                          28                               838    39
  Unknown                                           2                            \<1                              5      \<1
  **Hysterectomy**                                                                                                       
  No                                                631                          74                               1683   79
  Yes                                               221                          26                               454    21
  Unknown                                           2                            \<1                              2      \<1
  **Tubal ligation**                                                                                                     
  No                                                582                          68                               1335   62
  Yes                                               272                          32                               802    37
  Unknown                                           0                            0                                2      \<1

Abbreviations: BMI=body mass index; COC=combined oral contraceptives; FFTP=first full-term pregnancy; HT=hormone therapy.

###### Risk for epithelial ovarian cancer among parous women associated with exclusive use of combination oral contraceptives (COCs) before and after the first full-term pregnancy (FFTP), overall and by histotype

                                                            **All epithelial cancer**   **Histotype-specific**                                                                                                                                                            
  -------------------------------------------- ----- ----- --------------------------- ------------------------ --------------------------------- -------------- ----- ----- --------------------------------- -------------- ---- ---- --------------------------------- --------------
  **COC use**                                                                                                                                                                                                                                                             
  No                                            427   27               323                        45                          1.00                   referent     179   48                 1.00                   referent     46   41                1.00                   referent
  **Yes, exclusive use**                                                                                                                                                                                                                                                  
  Before and after FFTP                         535   25               119                        14                          0.45                 (0.34, 0.59)   64    15                 0.50                 (0.35, 0.72)   28   20                0.52                 (0.29, 0.92)
  Before FFTP                                   703   45               186                        26             0.56[b](#t2-fn3){ref-type="fn"}   (0.42, 0.75)   85    23    0.49[b](#t2-fn3){ref-type="fn"}   (0.35, 0.70)   38   34   0.47[b](#t2-fn3){ref-type="fn"}   (0.27, 0.83)
  After FFTP                                    444   28               211                        29             0.78[b](#t2-fn3){ref-type="fn"}   (0.61, 1.01)   111   30    0.76[b](#t2-fn3){ref-type="fn"}   (0.56, 1.04)   29   26   0.73[b](#t2-fn3){ref-type="fn"}   (0.41, 1.30)
  **Yes, duration of use (years)**                                                                                                                                                                                                                                        
  **Before and after FFTP**                                                                                                                                                                                                                                                      
   \<5                                          153    7               46                         5                           0.62                 (0.42, 0.92)   28     6                 0.75                 (0.46, 1.20)   11   8                 0.79                 (0.35, 1.64)
   5--\<10                                      183    9               36                         4                           0.39                 (0.26, 0.59)   22     5                 0.46                 (0.27, 0.76)   7    5                 0.29                 (0.11, 0.67)
   ⩾10                                          197    9               37                         4                           0.36                 (0.24, 0.54)   14     3                 0.33                 (0.17, 0.59)   10   7                 0.56                 (0.24, 1.18)
   Unknown                                       2    \<1               0                         0                                                                0     0                                                     0    0                                            
  per year of use[c](#t2-fn4){ref-type="fn"}                                                                                  0.94                 (0.91, 0.98)                            0.95                 (0.90, 1.00)                          0.91                 (0.83, 0.99)
  **Exclusively before FFTP**                                                                                                                                                                                                                                                    
   \<5                                          397   25               121                        17                          0.61                 (0.45, 0.83)   52    14                 0.50                 (0.34, 0.74)   26   23                0.56                 (0.30, 1.04)
   5--\<10                                      193   12               51                         7                           0.57                 (0.37, 0.85)   27     7                 0.62                 (0.37, 1.03)   7    6                 0.33                 (0.12, 0.81)
   ⩾10                                          112    7               13                         2                           0.22                 (0.11, 0.42)    5     1                 0.18                 (0.06, 0.44)   5    4                 0.35                 (0.10, 0.99)
   Unknown                                       1    \<1               1                        \<1                                                               1    \<1                                                    0    0                                            
  per year of use[c](#t2-fn4){ref-type="fn"}                                                                                  0.91                 (0.86, 0.96)                            0.92                 (0.86, 0.99)                          0.92                 (0.83, 1.01)
  **Exclusively after FFTP**                                                                                                                                                                                                                                                     
   \<5                                          270   17               128                        18                          0.84                 (0.63, 1.12)   67    18                 0.80                 (0.56, 1.15)   17   15                0.70                 (0.36, 1.35)
   5--\<10                                      107    7               48                         7                           0.74                 (0.49, 1.10)   24     6                 0.67                 (0.39, 1.11)   7    6                 0.84                 (0.31, 2.01)
   ⩾10                                          62     4               32                         4                           0.76                 (0.47, 1.22)   19     5                 0.82                 (0.45, 1.43)   4    4                 0.68                 (0.18, 1.97)
   Unknown                                       5    \<1               3                        \<1                                                               1    \<1                                                    1    1                                            
  per year of use[c](#t2-fn4){ref-type="fn"}                                                                                  0.98                 (0.95, 1.02)                            0.98                 (0.94, 1.04)                          0.97                 (0.88, 1.07)

Abbreviations: OR=odds ratio; 95% CI=95% confidence interval.

ORs adjusted for study site (Alberta, BC before 2005, BC after 2005), age (40--49, 50--59, 60--69, ⩾70 years), parity (1,2, ⩾3), age at FFTP (⩽24, 25--29, ⩾30 years), breastfeeding (never, ever), first degree female family history of breast or ovarian cancer (no, yes), tubal ligation (no, yes), and BMI (\<25, 25--29.9, 30--34.9, ⩾35 kg m^−2^).

*P*-value for difference in ORs, \<0.01.

Among COC users only.
